[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"lung-resection\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:lung-resection":28},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,4,0,[8,50,88,116],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":21,"studyType":22,"phases":4,"briefSummary":23,"conditions":24,"keywords":31,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":38,"lastUpdatePostDateStruct":39,"startDateStruct":42,"completionDateStruct":44,"leadSponsor":46,"locationsCount":49},"100641814","perioperative-quantitative-sensory-testing-and-incision-pain-mapping-in-thoracic-surgery-100641814",false,"NCT07653932","Perioperative Quantitative Sensory Testing and Incision Pain Mapping in Thoracic Surgery","Perioperative Pain Phenotyping and Incision Pain Mapping Using Quantitative Sensory Testing in Patients Undergoing Thoracoscopic or Robotic-assisted Lung Resection: A Prospective Observational Pilot Cohort Study","Inclusion Criteria:\n\n1. Male\n2. Scheduled to undergo elective thoracoscopic or robotic-assisted lung resection.\n3. American Society of Anesthesiologists physical status I to III.\n4. Able to understand and communicate adequately and to complete study questionnaires independently or with assistance from study staff.\n5. Willing to undergo QST assessment, perioperative venous blood sampling, and postoperative follow-up.\n6. Able and willing to provide written informed consent.\n\nExclusion Criteria:\n\n1. Definite chronic chest wall, shoulder, back, or upper limb pain with an average 2. Numeric Rating Scale score of 3 or higher during the preceding week.\n\n3\\. Definite painful neuropathic disease or long-term use of opioids or other analgesics for more than 2 weeks.\n\n4\\. Peripheral neuropathy, spinal cord disease, or other neurological disease that may substantially interfere with interpretation of QST results.\n\n5\\. Severe cognitive impairment, psychiatric disorder, communication disorder, or inability to complete questionnaires and QST assessments.\n\n6\\. Active infection, active autoimmune disease, or other disease condition that may substantially affect inflammatory protein measurements.\n\n7\\. Emergency surgery, conversion to open thoracotomy, extensive chest wall resection, or severe intraoperative complications.\n\n8\\. Any condition that, in the opinion of the investigator, makes the participant unsuitable for continued participation in the study.","MALE","18 Years",{"count":19,"type":20},46,"ESTIMATED","3 Months","OBSERVATIONAL","Postoperative pain remains a common and clinically important burden after thoracic surgery and may progress to chronic postsurgical pain. Conventional pain assessment mainly relies on patient-reported pain intensity and analgesic consumption, which may not fully capture peri-incisional sensory abnormalities, mechanical hyperalgesia, or central sensitization.\n\nThis prospective observational pilot cohort study aims to evaluate the feasibility and acceptability of perioperative quantitative sensory testing (QST) and incision pain mapping in adult patients undergoing elective thoracoscopic or robotic-assisted lung resection. Participants will undergo baseline assessment before surgery, serial postoperative pain assessments during the first 72 hours, QST and mechanical hyperalgesia pain mapping at 48-72 hours after surgery, and follow-up assessments at discharge, 1 month, and 3 months after surgery.\n\nThe primary feasibility outcomes include recruitment rate, QST completion rates, follow-up completion rates, QST-related discontinuation rate, study-related adverse events, and data completeness. The main clinical mechanistic outcome is the area of peri-incisional mechanical hyperalgesia at 48-72 hours after surgery. Secondary outcomes include acute postoperative pain intensity, pain burden over 72 hours, opioid consumption, quality of recovery, QST changes, pain-map characteristics, and chronic postsurgical pain at 3 months.\n\nThis study will not assign or modify therapeutic interventions. All anesthetic, surgical, and analgesic management will be determined by the routine clinical care team. The study is expected to provide feasibility data, preliminary effect estimates, and mechanistic information for future larger perioperative pain studies.",[25,26,27,28,29,30],"Postoperative Pain","Chronic Postsurgical Pain","Thoracic Surgery","Lung Resection","Mechanical Hyperalgesia","Central Sensitization",[32,33,34,35,36],"Quantitative sensory testing","QST","Incision pain mapping","Thoracoscopic surgery","Perioperative pain phenotype","NOT_YET_RECRUITING","2026-06-13",{"date":40,"type":41},"2026-06-17","ACTUAL",{"date":43,"type":20},"2026-06-08",{"date":45,"type":20},"2027-02-28",{"name":47,"class":48},"Tongji Hospital","OTHER",1,{"id":51,"slug":52,"hasResults":11,"nctId":53,"briefTitle":54,"officialTitle":55,"acronym":56,"eligibilityCriteria":57,"healthyVolunteers":11,"sex":58,"minAge":17,"maxAge":59,"enrollmentInfo":60,"targetDuration":4,"studyType":62,"phases":63,"briefSummary":65,"conditions":66,"keywords":72,"overallStatus":78,"whyStopped":4,"lastUpdateSubmitDate":79,"lastUpdatePostDateStruct":80,"startDateStruct":82,"completionDateStruct":84,"leadSponsor":86,"locationsCount":49},"100621011","the-primrose-trial-100621011","NCT07365072","The PRIMROSE Trial","A Randomised Controlled Trial to Evaluate the Impact of Thoracic PRehabilitation With Inspiratory Muscle tRaining cOmpared to Standard prEhabilitation in People With Lung Cancer for Surgical Treatment . The PRIMROSE Trial","PRIMROSE","Inclusion Criteria: Adults with lung cancer with surgically resectable disease who are referred for pre-treatment optimization with Prehab, from the lung cancer Multi-Disciplinary Teams (MDTs).\n\nThe referral criteria for Prehab is below:\n\n* ≥1 Medical Research Council (MRC) dyspnoea score\n* ≥1 World Health Organization (WHO) performance status (PS)\n* Age ≥ 70 years\n* Frailty index \\>3\n* Borderline or poor pulmonary function (forced expiratory volume in one second (FEV1) \\\u003C 50% or diffusion capacity for carbon monoxide (DLCO) \\\u003C50%)\n* Sedentary people despite having adequate FEV1 or DLCO\n* People who are eligible for surgical procedures, including endobronchial excision of tumour, or lobectomy, segmental resection, pneumonectomy or wedge resection, either via a minimally invasive approach or a standard thoracotomy approach\n\nAdditionally:\n\n* Participants will be included in the trial if they are capable of providing verbal and written consent for Prehab, and written consent for undergoing a surgical procedure for lung cancer\n* People over 18 years of age\n* All people will be considered regardless of their baseline respiratory muscle strength\n\nExclusion Criteria: Inclusion criteria not met\n\n* People diagnosed with other cancers namely, metastatic lung cancer, mesothelioma, sarcoma, mediastinal tumours, or benign diseases\n* People who decline Prehab\n* People who do not consent to Prehab, and do not attend Prehab. People who do not consent to surgery\n* People with a high cardiovascular risk for Prehab and awaiting investigations or interventions (including unstable angina and syncope)\n* People with a serious concomitant disorder that would compromise safety during Prehab\n* People with an abdominal hernia or recent abdominal surgery\n* People with a history of spontaneous pneumothorax and\u002For evidence of large bullae on radiological imaging\n* People with an inability to understand written and\u002For spoken English (only if carers are able to translate)\n* People with a perforated ear drum\n* People with worsening heart failure signs and symptoms after IMT\n* People with pulmonary hypertension\n* People who have suffered from or likely to suffer from costochondritis\n* If a participant was involved in a similar study, with potential to cause bias or conflict of interest then they will be excluded","ALL","90 Years",{"count":61,"type":20},100,"INTERVENTIONAL",[64],"NA","Smoking is a major cause for developing lung cancer. People diagnosed with lung cancer, may be offered surgery which offers a complete cure. Smoking also damages the lungs and compromises a person's lung function, resulting in shortness of breath. Breathlessness limits the ability to carry out daily physical activities and exercise and makes people vulnerable to developing post procedure complications and even death. Some people with surgically treatable lung cancer have a poor ability to exercise and compromised lung function and are not fit for surgery. They will instead be referred for radiation therapy, chemotherapy or palliative care. Surgery is the preferred treatment option.\n\nThe pulmonary rehabilitation program (Prehab) improves fitness levels. In addition, it improves the level of breathlessness, exercise capacity and vulnerability of people with lung cancer, with the aim of making them fit for safe surgery. By adding a breathing training device to the Prehab program, the investigators aim to further improve participants fitness for surgery, lower their risk of developing complications and the time spent in hospital after the procedure. The breathing training device is called an inspiratory muscle training device. The hand-held device helps to train and strengthen the breathing muscles, which are then able to work more effectively. After the procedure, participants may be able to breathe and exercise more easily reducing their risk of developing complications and improving outcomes.\n\nThe study will compare two groups of people with lung cancer having surgical removal of part of the lung, at a specialist hospital . One group will receive standard Prehab and inspiratory muscle training with the device prior to the procedure; patients in the second group with receive standard Prehab prior to the procedure. Participants will be followed up for twelve months.",[67,28,68,69,70,71],"Cancer","Inspiratory Muscle Training","Prehabilitation","Respiratory Complications","Length of Hospital Stay",[73,67,74,69,75,76,77],"Inspiratory muscle training","Lung resection","Lung surgery","Randomised control trial","length of hospital stay","RECRUITING","2026-01-28",{"date":81,"type":41},"2026-01-30",{"date":83,"type":41},"2025-05-01",{"date":85,"type":20},"2027-05-01",{"name":87,"class":48},"Swansea Bay University Health Board",{"id":89,"slug":90,"hasResults":11,"nctId":91,"briefTitle":92,"officialTitle":93,"acronym":94,"eligibilityCriteria":95,"healthyVolunteers":11,"sex":58,"minAge":17,"maxAge":4,"enrollmentInfo":96,"targetDuration":4,"studyType":62,"phases":98,"briefSummary":99,"conditions":100,"keywords":102,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":107,"lastUpdatePostDateStruct":108,"startDateStruct":110,"completionDateStruct":112,"leadSponsor":114,"locationsCount":49},"100577771","prehabilitation-for-lung-cancer-patients-undergoing-lung-resection-100577771","NCT06802627","Prehabilitation for Lung Cancer Patients Undergoing Lung Resection","Influence of Prehabilitation on Postoperative Pulmonary Complications in Patient Undergoing Lung Resection Surgery","Fit4LungNeo","Inclusion Criteria:\n\n* Adult patients accepted for lung resection surgery, due to lung cancer, at the Cardiothoracic Department of Unidade Local de Saúde São João\n* Not included in any type of prehabilitation program\n\nExclusion Criteria:\n\n* Diagnosis of cardiac, or hematological or neurologic diseases\n* Pulmonary hypertension\n* Renal failure\n* Patients that underwent previous thoracic surgery\n* Patients submitted to pneumectomy\n* Patients with cognitive and mental disorders\n* Patients with impairments in autonomous deambulation\n* Patients already included in any prehabilitation program",{"count":97,"type":20},200,[64],"Lung surgical resection is the gold standard treatment for earlier stages of lung cancer patients. Nevertheless, postoperative pulmonary complications (PPC) are frequent, related to morbidity and mortality, increasing length of hospital stay (LOS), hospital costs, delaying adjuvant treatments, and patients suffering. The PPC often occurs on postoperative days, even after hospital discharge. Prehabilitation might reduce PPC, although few studies have compared the effectiveness of different training protocols, and no information is available regarding the possible benefits of expiratory muscle training. Moreover, there are no comparisons of the cost-benefits of other protocols in patients submitted to lung resection surgery.\n\nThis project investigates the effectiveness of and compares four different prehabilitation protocols in reducing PPC and LOS in patients selected for lung cancer resections.\n\nParticipants will be individuals referred to surgical resection due to lung cancer. Patients who meet the inclusion criteria will be invited to participate in the study. After clinical data collection, patients will be randomly allocated (simple method) into four groups \\[Control - CG, receiving an education session; Inspiratory muscle training group (IMT-G) receiving education session plus inspiratory muscle training (IMT); expiratory muscle training group (EMT-G) receiving education session plus expiratory muscle training (EMT); global exercise training group (GET-G) receiving education session plus a general exercise training (GET)\\], and evaluated for functional capacity (pulmonary function, respiratory muscle function, physical fitness, daily physical activity, dyspnoea, fatigue, quality of life, anxiety, depression, and a 24-hour food diary. Afterward, all patients will receive an education class and written information regarding healthy habits to follow before, during, and after hospital discharge. Patients allocated to exercise groups will start the prehabilitation intervention for two weeks. After the intervention, patient assessments will be repeated. After that, patients will be submitted to surgery, and anesthetic and surgical procedure data will be collected. During hospital recovery, all patients will receive physiotherapy and any etiological complications and the LOS will be recorded according to medical criteria. After hospital discharge, PPC will be monitored and recorded for 30 days; by then, patients will be submitted to the final assessment.",[101,28],"Lung Cancer",[69,74,103,104,105,106],"Exercise training","Postoperative pulmonary complications","Respiratory muscle training","Education","2025-01-24",{"date":109,"type":41},"2025-01-31",{"date":111,"type":20},"2025-03-01",{"date":113,"type":20},"2027-11-30",{"name":115,"class":48},"Universidade do Porto",{"id":117,"slug":118,"hasResults":11,"nctId":119,"briefTitle":120,"officialTitle":120,"acronym":121,"eligibilityCriteria":122,"healthyVolunteers":11,"sex":58,"minAge":17,"maxAge":4,"enrollmentInfo":123,"targetDuration":4,"studyType":62,"phases":125,"briefSummary":126,"conditions":127,"keywords":129,"overallStatus":78,"whyStopped":4,"lastUpdateSubmitDate":133,"lastUpdatePostDateStruct":134,"startDateStruct":136,"completionDateStruct":138,"leadSponsor":140,"locationsCount":49},"100577324","bioimpedance-analysis-in-perioperative-assessment-in-thoracic-surgery-100577324","NCT06796816","Bioimpedance Analysis in Perioperative Assessment in Thoracic Surgery","BIVA-18","Inclusion Criteria:\n\n\\- Patients undergoing pulmonary resection surgery for primary neoplasm within a one-year timeframe.\n\nExclusion Criteria:\n\n* Patients with chronic atrial fibrillation (AF).\n* Patients who have previously undergone major pulmonary resection.\n* Patients with pacemakers or implantable devices, as the use of bioimpedance vector analysis (BIVA) may be contraindicated.",{"count":124,"type":20},1000,[64],"The assessment of surgical and postoperative risks in thoracic surgery is a field of significant interest because the surgical procedure causes substantial changes in the body's homeostasis.\n\nThe postoperative course is characterized by considerable clinical variability compared to the preoperative classification, which highlights more homogeneous data among various patient groups. This variability appears to result from individual differences in response to extensive pulmonary resections. Notably, the homogeneity of preoperative data does not correlate with the greater variability observed in the postoperative course.\n\nThe application of algorithms derived from BIVA in bioimpedance studies has proven particularly useful for prognostic assessments in oncology, as it can evaluate a patient's hydration status and muscle reserves at the time of diagnosis or the start of clinical\u002Fsurgical treatment.\n\nUnderstanding body composition, particularly the quantity and\u002For quality of muscle mass, is essential for diagnosing sarcopenia.\n\nBy passing a low-intensity alternating current (imperceptible to the patient) through the body, BIVA measures provide insights into body water distribution (both intracellular and extracellular), lean mass and skeletal muscle mass. Overall, the test offers a detailed picture of hydration status and skeletal muscle composition.\n\nAnother validated tool for assessing sarcopenia, which provides information on both muscle quantity (via cross-sectional area measurements) and muscle quality (via muscle density measurements), is computed tomography (CT). CT imaging is typically performed for diagnostic and staging purposes before surgery in thoracic surgery patients, either alone or in combination with positron emission tomography (PET).\n\nOur study will focus on assessing correlations between clinical, imaging, and bioimpedance data and postoperative outcomes, with particular attention to the incidence of atrial fibrillation (AF), pulmonary atelectasis requiring treatment, and increased pleural drainage production.\n\nAdditionally, we will evaluate the relationship between the surgical approach (open surgery vs. video-assisted thoracoscopic surgery, or VATS) and short-term bioimpedance values.",[28,128],"Adenocarcinoma of Lung",[130,131,132],"bioimpedence","lung cancer","sarcopenia","2025-01-22",{"date":135,"type":41},"2025-01-28",{"date":137,"type":41},"2019-04-02",{"date":139,"type":20},"2026-12",{"name":141,"class":142},"Azienda USL Reggio Emilia - IRCCS","OTHER_GOV"]